Host-Directed Inhibitors of Myxovirus Replication
粘病毒复制的宿主定向抑制剂
基本信息
- 批准号:8566072
- 负责人:
- 金额:$ 17.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-03-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcute DiseaseAddressAdmission activityAdverse effectsAffectAntiviral AgentsAntiviral TherapyBiological AssayCell LineCellsChemicalsClinicalClinical assessmentsComplementDevelopmentDisease ManagementEligibility DeterminationEvolutionExerciseExposure toFailureFamilyFamily memberFamily suidaeFoundationsFutureGoalsHendra VirusHousingHumanHuman Cell LineHuman respiratory syncytial virusIndividualLeadLicensingLife Cycle StagesLung diseasesMeasles virusMolecularMolecular TargetMonitorMutationMyxovirusMyxovirus diseaseNipah VirusOrthomyxoviridaeParamyxoviridaeParamyxovirusPathway interactionsPharmaceutical PreparationsPharmacologic SubstancePhasePreventionProductionPropertyProtocols documentationPublic HealthRNA VirusesResistanceResistance developmentRespiratory syncytial virusRiskScreening procedureSolidStagingTechnologyTherapeuticTimeTissuesVaccinesViralVirusVirus Replicationbasebiodefenseclinically significantcostcounterscreendesigndrug candidatedrug developmentestablished cell linefight againstflexibilityhigh throughput screeninghuman morbidityhuman mortalityimprovedindexinginfluenzavirusinhibitor/antagonistinnovationloss of functionmanufacturing processmeetingsmembernext generationnovelnovel therapeuticspandemic diseaseparainfluenza viruspathogenpre-clinicalprogramsscaffoldsmall moleculetherapeutic targettransmission processvaccine efficacyviral resistance
项目摘要
It is the overarching goal of this project to develop host-directed inhibitors of myxovirus replication that are designed to transform the prevalent one-drug, one-bug approach of antiviral therapy to a one-drug, multiple-bugs paradigm. This pioneering approach aims to systemically address two major challenges frequently associated with viral therapeutics: pre-existing or rapidly developing resistance to the inhibitor, and a narrow indication spectrum of many antiviral drugs, which are aggravated by cost and low flexibility of the current pharmaceutical manufacturing process, viral evolution and the emergence of novel, highly pathogenic agents. We hypothesize that these obstacles can be overcome through therapeutic targeting of host cell pathways required for virus propagation, since individual viral mutations will likely not compensate for loss-of-function of a host pathway, and viruses of related families frequently depend on overlapping sets of host components for completion of their life cycle. Considering a higher potential for drug-induced side effects that is intrinsically associated with a host-directed approach, pathogens of the myxovirus families such as influenza virus, Nipah virus and respiratory syncytial virus that are predominantly associated with acute disease emerge as particularly suitable for this therapeutic strategy, since treatment time and thus host exposure to the drug remain limited.
To meet future clinical needs of antiviral therapy, this project will build on the solid foundation provided by our established anti-myxovirus program and pursue the identification and molecular characterization of innovative small-molecule antivirals to establish a tangible foundation for the future development of confirmed therapeutic candidate status towards IND-filing status. Through a combination of automated screening and chemical elaboration, our program has previously identified a pool of small-molecule hits with broadened nanomolar to low-micromolar activity against influenza virus and members of the paramyxovirus family. In this supplement project that will adhere to a set of clearly defined milestones, a novel, innovative dual-myxovirus pathogen screening protocol will be implemented to further diversify the portfolio of existing myxovirus inhibitors, alleviating the risk of early stage failure (aim 1). In search of a subset of structurally diverse lead scaffolds that meet these milestones and warrant further development, active concentrations of newly discovered and existing hits will be determined for a diverse panel of cell lines and primary cells, the effect on exposed cells profiled, the point-of-arrest in virus replication assessed, and, for selected leads with the highest antiviral potency, the broader pathogen indication spectrum, molecular target, and key ADME properties determined (aim 2). It is the goal of these exercises to identify a lead scaffold and at least one structurally unrelated alternative suitable for synthetic development and pre-clinical assessment.
该项目的总体目标是开发宿主导向的黏液病毒复制抑制剂,旨在将流行的一药一虫抗病毒治疗方法转变为一药多虫范式。这种开创性的方法旨在系统地解决与病毒疗法经常相关的两个主要挑战:预先存在或迅速发展的对抑制剂的耐药性,以及许多抗病毒药物的狭窄适应症,这是由于当前制药工艺的成本和低灵活性,病毒进化和新型高致病性药物的出现而加剧的。我们假设这些障碍可以通过针对病毒传播所需的宿主细胞通路的治疗性靶向来克服,因为单个病毒突变可能无法弥补宿主通路的功能丧失,并且相关家族的病毒经常依赖于重叠的宿主组分集来完成其生命周期。考虑到药物引起的副作用的可能性较高,这与宿主导向的方法内在相关,黏液病毒家族的病原体,如流感病毒、尼帕病毒和呼吸道合胞病毒,主要与急性疾病相关,因此特别适合这种治疗策略,因为治疗时间和宿主接触药物的时间仍然有限。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard K. Plemper其他文献
Cryo-Electron Tomography Provides Insight into the Native Architecture of the Measles Virus Assembly Site
冷冻电子断层扫描可深入了解麻疹病毒装配位点的原生结构
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:2.8
- 作者:
J. Strauss;Ke Zunlong;Richard K. Plemper;E. Wright - 通讯作者:
E. Wright
Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity
ERDRP-0519 治疗麻疹病毒聚合酶可抑制所有 RNA 合成活性
- DOI:
10.1101/2020.09.23.311043 - 发表时间:
2020 - 期刊:
- 影响因子:6.7
- 作者:
R. Cox;Julien Sourimant;M. Govindarajan;M. Natchus;Richard K. Plemper - 通讯作者:
Richard K. Plemper
The Near-to-Native-State Architecture of Measles Virus Assembly Sites and Isolated Measles Virus Particles
麻疹病毒组装位点和分离的麻疹病毒颗粒的接近天然状态的结构
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:2.8
- 作者:
E. Wright;J. Strauss;Ke Zunlong;Cheri M. Hampton;Fredrick Leon;M. Brindley;Richard K. Plemper - 通讯作者:
Richard K. Plemper
Capturing Enveloped Viruses on Affinity Grids for Downstream Cryo-Electron Tomography Applications
在亲和网格上捕获包膜病毒以用于下游冷冻电子断层扫描应用
- DOI:
10.1017/s1431927613002274 - 发表时间:
2013 - 期刊:
- 影响因子:2.8
- 作者:
Gabriella Kiss;Xuemin Chen;J. Holl;M. Brindley;P. Campbell;A. Lauren;Byrd;J. Steel;D. Steinhauer;C. Afonso;Richard K. Plemper;Paul;Spearman;Deborah F. Kelly;E. Wright - 通讯作者:
E. Wright
121 INTESTINAL MICROBIOME INFLUENCES SEVERITY OF RESPIRATORY VIRAL INFECTION VIA IMPACTING ALVEOLAR MACROPHAGES
- DOI:
10.1016/s0016-5085(23)01001-6 - 发表时间:
2023-05-01 - 期刊:
- 影响因子:
- 作者:
Vu L. Ngo;Carolin M. Lieber;Richard K. Plemper;Andrew T. Gewirtz - 通讯作者:
Andrew T. Gewirtz
Richard K. Plemper的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard K. Plemper', 18)}}的其他基金
Project 1 – Development of Orally Bioavailable beta-CoV Inhibitors
项目 1 — 口服生物可利用的 β-CoV 抑制剂的开发
- 批准号:
10513942 - 财政年份:2022
- 资助金额:
$ 17.12万 - 项目类别:
Polymerase Inhibitors of Respiratory Syncytial Virus
呼吸道合胞病毒聚合酶抑制剂
- 批准号:
10666509 - 财政年份:2020
- 资助金额:
$ 17.12万 - 项目类别:
Polymerase Inhibitors of Respiratory Syncytial Virus
呼吸道合胞病毒聚合酶抑制剂
- 批准号:
10425285 - 财政年份:2020
- 资助金额:
$ 17.12万 - 项目类别:
Polymerase Inhibitors of Respiratory Syncytial Virus
呼吸道合胞病毒聚合酶抑制剂
- 批准号:
10034283 - 财政年份:2020
- 资助金额:
$ 17.12万 - 项目类别:
Polymerase Inhibitors of Respiratory Syncytial Virus
呼吸道合胞病毒聚合酶抑制剂
- 批准号:
10199980 - 财政年份:2020
- 资助金额:
$ 17.12万 - 项目类别:
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses
针对季节性和高致病性流感病毒的广谱抑制剂的开发
- 批准号:
10544324 - 财政年份:2019
- 资助金额:
$ 17.12万 - 项目类别:
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses
针对季节性和高致病性流感病毒的广谱抑制剂的开发
- 批准号:
10080034 - 财政年份:2019
- 资助金额:
$ 17.12万 - 项目类别:
Drug discovery against lyssaviruses by high thoughput screening
通过高通量筛选发现抗狂犬病病毒药物
- 批准号:
9218526 - 财政年份:2016
- 资助金额:
$ 17.12万 - 项目类别:
Identification and Hit-to-Lead Development of Influenza A Virus Inhibitors
甲型流感病毒抑制剂的鉴定和先导化合物开发
- 批准号:
8955538 - 财政年份:2015
- 资助金额:
$ 17.12万 - 项目类别:
Novel Therapeutics against Respiratory Syncytial Virus Infection
对抗呼吸道合胞病毒感染的新疗法
- 批准号:
8662435 - 财政年份:2014
- 资助金额:
$ 17.12万 - 项目类别:
相似海外基金
Improving Acute Disease Management for Patients with Alzheimer's Disease and Related Dementias
改善阿尔茨海默病和相关痴呆症患者的急性疾病管理
- 批准号:
10712647 - 财政年份:2001
- 资助金额:
$ 17.12万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
6247642 - 财政年份:1997
- 资助金额:
$ 17.12万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
3718999 - 财政年份:
- 资助金额:
$ 17.12万 - 项目类别:
Neurophysiological alterations in multiple sclerosis patients during acute disease acivity
多发性硬化症患者急性疾病活动期间的神经生理学变化
- 批准号:
465668867 - 财政年份:
- 资助金额:
$ 17.12万 - 项目类别:
Research Grants
SIVMAC 1NEF ALLELE: LYMPHOCYTE ACTIVATION & ACUTE DISEASE IN MACAQUE MONKEYS
SIVMAC 1NEF 等位基因:淋巴细胞激活
- 批准号:
3719026 - 财政年份:
- 资助金额:
$ 17.12万 - 项目类别: